<DOC>
	<DOCNO>NCT01221285</DOCNO>
	<brief_summary>This trial biomarker-based pilot study safety Cockroach Subcutaneous Immunotherapy Cockroach-sensitive Adults ( SCITCO ) history perennial allergic rhinitis , asthma , .</brief_summary>
	<brief_title>Development Cockroach Immunotherapy Inner-City Asthma Consortium</brief_title>
	<detailed_description>Scientific evidence show , past two decade , combination cockroach allergy cockroach exposure one important factor contribute dramatic increase asthma morbidity see inner city child asthma . Therefore , major goal Inner City Asthma Consortium ( ICAC ) evaluate efficacy cockroach immunotherapy inner city asthma .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic , Perennial</mesh_term>
	<criteria>Have history perennial allergic rhinitis , asthma , , minimum 1 year study entry . For asthma : diagnosis asthma define report participant clinical diagnosis asthma make physician year ago participant 's asthma must well control define : forced expiratory volume one second ( FEV1 ) great equal 80 % predict value without controller medication albuterol use 3 day per week previous 2 week asthma symptom ( include exercise prophylaxis ) Are sensitive German cockroach ( Blattella germanica ) document positive ( &gt; = 3 mm great negative control ) skin prick test result detectable German cockroach specific IgE ( &gt; =0.35 kUA/L ) Have know contraindication therapy glycerinated German ( Blattella germanica ) cockroach allergenic extract Are willing sign write Informed Consent prior initiation study procedure Are pregnant lactating . Females must abstinent use medically acceptable birth control method throughout study ( e.g . oral , subcutaneous , mechanical , surgical contraception ) Are unable perform spirometry screen Have asthma severity classification recruitment severe persistent , use National Asthma Education Prevention Program ( NAEPP ) classification , evidence least one following : require dose great 500 mcg fluticasone per day equivalent another inhaled corticosteroid receive 2 course oral parenteral corticosteroid within last 12 month treat depot steroid within last 12 month hospitalize asthma within 6 month prior recruitment lifethreatening asthma exacerbation require intubation , mechanical ventilation , result hypoxic seizure within 2 year prior recruitment Do access phone ( need scheduling appointment ) Have receive allergen immunotherapy ( SLIT SCIT ) last 12 month prior recruitment plan initiate resume allergen immunotherapy study . Subjects receive placebo therapy BioCSI protocol ( A Biomarkerbased Pilot Study Cockroach Sublingual Immunotherapy Cockroach Sensitive Adults With Asthma and/or Perennial Allergic Rhinitis , ICAC12 , NCT00829985 ) eligible participate study Have previously treat antiIgE therapy within 1 year recruitment Have receive investigational drug 30 day prior recruitment plan use investigational drug study Refuse sign Epinephrine Autoinjector Training Form Do primarily speak English Plan move area study period Have history idiopathic anaphylaxis anaphylaxis grade 2 high define protocol Have unstable angina , significant arrhythmia , uncontrolled hypertension , history autoimmune disease , chronic immunological disease opinion investigator might interfere evaluation investigational agent pose additional risk participant Are use tricyclic antidepressant betaadrenergic blocker drug ( either oral topical route [ ] administration )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Cockroach</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Subcutaneous immunotherapy</keyword>
	<keyword>Inner city asthma</keyword>
</DOC>